Log in

2142 HBM Holdings Ltd. HKEX · China

HBM Holdings (2142) news

HBM Holdings Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2142, recorded under China. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest HBM Holdings news

We have not published a story on HBM Holdings yet. When there is news, it will appear here.

Questions about HBM Holdings

What is the ticker symbol of HBM Holdings?

HBM Holdings Ltd. trades under the ticker 2142 on HKEX.

Where is HBM Holdings listed?

HBM Holdings Ltd. is listed on HKEX. Our directory also records these other listings: GETTEX:6XY.

Which country or territory is HBM Holdings listed under?

Our directory records HBM Holdings Ltd. under China.

What does HBM Holdings do?

Our directory classifies HBM Holdings Ltd. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.

What is the ISIN of HBM Holdings?

The ISIN recorded for HBM Holdings Ltd. is KYG4403H1002.

Does aibio.space cover HBM Holdings?

aibio.space lists HBM Holdings Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to HBM Holdings?

Companies in our directory listed in the same country and business area as HBM Holdings: Guilin Sanjin Pharmaceutical Co., Tianjin Tianyao Pharmaceuticals Co., Dong-E-E-Jiao Co., Jilin Province Huinan Changlong Bio Pharmacy Co., Zhongzhi Pharmaceutical Holdings, Zhejiang Medicine Co..

Investor discussion: HBM Holdings

Members talk about HBM Holdings (2142). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at HBM Holdings, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; AND NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  3. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  4. Financings

    Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING. Source

  5. Financings

    Share or debt issue: COMPLETION OF ISSUE OF SUBSCRIPTION SHARES UNDER GENERAL MANDATE. Source

  6. Financings

    Share or debt issue: INSIDE INFORMATION - ISSUE OF SUBSCRIPTION SHARES UNDER GENERAL MANDATE AND COLLABORATION WITH ASTRAZENECA. Source

Press releases

Headlines of HBM Holdings's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT - NMPA APPROVAL OF BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTION) FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS

  2. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT AND THE 2026 INTERIM REPORT

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - NONA BIOSCIENCES DEVELOPS THE WORLD'S FIRST LANGUAGE MODEL TRAINED ON FULLY HUMAN HEAVY-CHAIN-ONLY ANTIBODIES

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IN RELATION TO SERIES A FINANCING OF THE COMPANY'S PARTNER SOLSTICE ONCOLOGY

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE II INTERIM RESULTS AND INITIATION OF PHASE III STUDY OF HBM9378/WIN378 IN ASTHMA

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT

  7. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT - RESIGNATION OF EXECUTIVE DIRECTOR; APPOINTMENT OF EXECUTIVE DIRECTORS; AND CHANGE OF AUTHORIZED REPRESENTATIVE

  8. HKEXnews

    RESIGNATION OF EXECUTIVE DIRECTOR; APPOINTMENT OF EXECUTIVE DIRECTORS; AND CHANGE OF AUTHORIZED REPRESENTATIVE

  9. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - NMPA IND APPROVAL FOR HBM7004 FOR THE TREATMENT OF ADVANCED SOLID TUMORS

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC COLLABORATION WITH SINOPHARM

  13. HKEXnews

    POSITIVE PROFIT ALERT

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR HBM7575 FOR ASTHMA BY THE NMPA

  15. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 25 JUNE 2026

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - JOINTLY INITIATE MEGASTREAM TECHBIO WITH BIOMAP

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT - JURY VERDICT IN U.S. PATENT INFRINGEMENT LITIGATION

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF IND APPLICATION FOR HBM7004 FOR THE TREATMENT OF ADVANCED SOLID TUMORS

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT - FIRST PATIENTS DOSED IN PHASE II SIRIUS COPD STUDY OF HBM9378/WIN378, A FULLY HUMAN ULTRA LONG-ACTING ANTI-TSLP ANTIBODY

  20. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RELEASE OF PRECLINICAL DATA FOR LET003, FIRST AI-ENABLED DRUG CANDIDATE, A NEXT-GENERATION ACVR2A/2B-TARGETING ANTIBODY FOR OBESITY TREATMENT

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2142 on TradingView.

Listing details

HBM Holdings Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2142, recorded under China. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
HBM Holdings Ltd.
Ticker
2142
Listing
HKEX
Country or territory
China
Business scope
Biopharma / pharmaceutical profile checked
ISIN
KYG4403H1002
Other listed symbols
GETTEX:6XY
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.